•  
  •  
  •  
  •  

2026-08-17 22:08:32

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Alluri Sitarama Raju International Airport Commences Commercial Operations Gateway of the East Now Open to Fly
  • Om Infra Bags ₹29.01 Crore Supplementary Order under Jal Jeevan Mission in Uttar Pradesh
  • DCX Systems and Subsidiary Bag Orders Worth ₹18.28 Crore for Cable Harnesses and PCB Assemblies
  • Stanley Lifestyles Appoints CA. Sudhir Iyer as Group Chief Financial Officer
  • Shraddha Prime Projects Ltd admitted for Trading on NSE under the 'Permitted to Trade' Category

Keywords Selected:  SMSPharmaceuticals

Stock Report

  • SMS Pharmaceuticals Limited Reports Unaudited Financial Results for Q1 FY27
  • SMS Pharmaceuticals Reports Robust FY26 Performance: PAT Soars 48% and EBITDA Margins Expand to 19%
  • Successful completion of USFDA inspection at Vizag facility
  • SMS Pharmaceutical's associate company, VKT Pharma, receives US FDA approval for its reformulated Ranitidine
  • SMS Pharmaceuticals Ltd Q2 FY26 consolidated PAT increases to Rs. 25.31 crores
  • SMS Pharmaceuticals Ltd receives EIR from USFDA for Central Laboratory Analytical Services
  • SMS Pharmaceuticals Ltd posts consolidated Q1FY26 net profit of Rs. 20.49 crores
  • SMS Pharmaceuticals Ltd successfully completes USFDA inspection at Central Laboratory Analytical Services
  • SMS Pharmaceuticals Ltd's Vizag plant receives WHO Geneva prequalification
  • Successful completion of USFDA inspection at SMS Pharmaceuticals Ltd's Hyderabad facility
  • SMS Pharma receives EDQM Certification to supply to Ibuprofen in Europe
  • SMS Pharmaceuticals Ltd Q1 FY25 consolidated profit at Rs. 16.47 crores
  • EDQM conducts GMP inspection of SMS Pharmaceuticals Ltd's API facility
  • SMS Pharmaceuticals Limited reports robust Q3FY24 operational performance
  • SMS Pharmaceuticals Ltd reports rise in Q1FY24 consolidated PAT to Rs. 8.80 crore
  • SMS Pharmaceuticals Ltd Q4FY23 consolidated PAT at Rs. 6.21 crores
  • SMS Pharmaceuticals Ltd reports consolidated net profit of Rs. 3.76 crore
  • SMS Pharmaceuticals Ltd Q1FY23 consolidated loss at Rs. 12.76 crores
  • SMS Pharmaceuticals Ltd receives Certificate of Suitability approval for Ibuprofen by EDQM
  • SMS Pharmaceuticals successfully completes remote regulatory assessment by USFDA
  • SMS Pharmaceuticals Q3FY22 consolidated PAT at Rs. 8.96 crores
  • SMS Pharmaceuticals Ltd posts consolidated PAT of Rs. 23.02 crore in Q2 FY2021-22

Latest Post

  • Alluri Sitarama Raju International Airport Commences Commercial Operations Gateway of the East Now Open to Fly
  • Om Infra Bags ₹29.01 Crore Supplementary Order under Jal Jeevan Mission in Uttar Pradesh
  • DCX Systems and Subsidiary Bag Orders Worth ₹18.28 Crore for Cable Harnesses and PCB Assemblies
  • Stanley Lifestyles Appoints CA. Sudhir Iyer as Group Chief Financial Officer
  • Shraddha Prime Projects Ltd admitted for Trading on NSE under the 'Permitted to Trade' Category


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025